Bacterial resistance: A worldwide problem

Diagnostic Microbiology and Infectious Disease

Volumn 31, Issue 2, 1998, Pages 379-388

  Jones, Ronald N ^a   Pfaller, Michael A ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAMASE; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; GLYCOPEPTIDE; IMIPENEM; MEROPENEM; OXACILLIN; PENICILLIN G;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTEREMIA; BACTERIAL INFECTION; BACTERIUM ISOLATION; CITROBACTER FREUNDII; CONFERENCE PAPER; DRUG POTENCY; ENTEROBACTER; GRAM NEGATIVE INFECTION; HOSPITAL PATIENT; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SERRATIA; STREPTOCOCCUS;

EID: 0031779855     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(98)00037-6     Document Type: Conference Paper

References (55)

1. Ballow C.H., Jones R.N., Johnson D.M., Deinhart J.A., Schentag J.J. Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. Diagn Microbiol Infect Dis. 29:1997;173-186.
2. Barry A.L., Pfaller M.A., Fuchs P.C., Packer R.R. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. medical centers in 1992 and 1993. Antimicrob Agents Chemother. 38:1994;2419-2425.
3. Bauernfeind A., Jungwirth R., Schweighart S. In vitro activity of meropenem, imipenem, and penem HRE 664 and ceftazidime against clinical isolates from West Germany. J Antimicrob Chemother. 24:(suppl A):1989;73-84.
4. Breiman R.F., Butler J.C., Tenover F.C., Elliott J.A., Facklam R.R. Emergence of drug-resistant pneumococcal infections in the United States. JAMA. 271:1994;1831-1835.
5. Bush K., Jacoby G.A., Medeiros A.A. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother. 39:1995;1211-1233.
6. Chanal C., Sirot D., Chanal M., Cluzel M., Sirot J., Cluzel R. Comparative in vitro activity of meropenem against clinical isolates including Enterobacteriaceae with expanded-spectrum β-lactamases. J Antimicrob Chemother. 24:(suppl A):1989;133-141.
7. Chanal C., Sirot D., Romaszko J.P., Bret L., Sirot J. Survey of extended β-lactamases among Enterobacteriaceae. J Antimicrob Chemother. 38:1996;127-132.
8. Cormican M.G., Jones R.N. Emerging resistance to antimicrobial agents in Gram-positive bacteria, enterococci, staphylococci, and non-pneumococcal streptococci. Drugs. 51:(suppl 1):1996;6-12.
9. Coudron P.E., Moland E.S., Sanders C.C. Occurrence and detection of extended-spectrum β-lactamases in members of the family Enterobacteriaceae at a Veterans Medical Center seek and you may find . J. Clin Microbiol. 35:1997;2593-2597.
10. Doern G.V., Brueggemann A.B., Holley H.P., Rauch A.M. Antimicrobial resistance with Streptococcus pneumoniae recovered from outpatients in the United States during 1994-95 results of a 30-center national surveillance study . Antimicrob Agents Chemother. 40:1996;1208-1213.
11. Edwards J.R. Meropenem a microbiological overview . J Antimicrob Chemother. 36:(suppl A):1995;1-17.
12. Elting L.S., Rubenstein E.B., Rolston K.V.I., Bodey G.P. Outcomes of bacteremia in patients with cancer and neutropenia observations from two decades of epidemiological and clinical trials . Clin Infect Dis. 25:1997;247-259.
13. Fey P.D., Climo M.W., Archer G.L. Determination of the chromosomal relationship between mec A and gyr A in methicillin-resistant coagulase-negative staphylococci. Antimicrob Agents Chemother. 42:1998;306-312.
14. Gonzales R., Steiner J.F., Sande M.A. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA. 278:1997;901-904.
15. Gordon S., Swenson J.M., Hill B.C., Pigott N.E., Facklam R.R., Cooksey R.C., Thornsberry C., Jarvis W.R., Tenover F.C. Antimicrobial susceptibility patterns of common and unusual species of enterococci causing infections in the United States. J Clin Microbiol. 30:1992;2372-2378.
16. Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., Tenover F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 40:1997;135-136.
17. Hoban D.J., Jones R.N., Yamane N., Frei R., Trilla A., Pignatari A.C. In vitro activity of three carbapenem antibiotics comparative studies with biapenem (L-627), imipenem, and meropenem against aerobic pathogens isolated world-wide . Diagn Microbiol Infect Dis. 17:1993;299-305.
18. Jones R.N. Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. Am J Med. 100:(suppl 6A):1996;3S-12S.
19. Jones R.N. The emergent needs for basic research, education, and surveillance of antimicrobial resistance problems facing the report from the American Society for Microbiology Task Force on antibiotic resistance . Diagn Microbiol Infect Dis. 25:1996;153-161.
20. Jones R.N., Aldridge K.E., Allen S.D., Barry A.L., Fuchs P.C., Gerlach E.H. Multicenter in vitro evaluation of SM-7338, a new carbapenem. Antimicrob Agents Chemother. 33:1989;562-565.
21. Jones R.N., Barry A.L., Gardiner R.V., Packer R.R. The prevalence of staphylococcal resistance to penicillinase-resistant penicillins a retrospective and prospective trial of isolates from 40 medical centers . Diagn Microbiol Infect Dis. 12:1989;383-394.
22. Jones R.N., Baquero F., Privitera G., Inoue M., Wiedemann B. Inducible β-lactamase-mediated resistances to third-generation cephalosporins. Clin Microbiol Infect. 3:(suppl 1):1997;S7-S20.
23. Jones R.N., Jacobs M.R., Washington J.A., Pfaller M.A. A 1994-95 survey of Haemophilus influenzae susceptibility to ten orally administered agents a 187 clinical laboratory center sample in the United States . Diagn Microbiol Infect Dis. 27:1996;75-83.
24. Jones R.N., Kehrberg E.N., Erwin M.E., Anderson S.C. Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States. I. Study on the threat of emerging resistances real or perceived? Diagn Microbiol Infect Dis. 19:1994;203-215.
25. Jones R.N., Marshall S.A., Pfaller M.A., Wilke W.W., Hollis R.J., Erwin M.E., Edmond M.B., Wenzel R.P. Nosocomial enterococcal blood stream infections in the SCOPE Program antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy . Diagn Microbiol Infect Dis. 29:1997;95-102.
26. Jones R.N., Pfaller M.A., Doern B.V., Verhoef Jones M., Sader H.S. Initial report of a longitudinal, international antimicrobial surveillance study (SENTRY) Alarming resistance rates in monitored sites (68 medical centers) in the USA, Canada, South America, and Europe, abstr. E-109 . Abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada. 1997;American Society for Microbiology, Washington, DC.
27. Jones R.N., Sader H.S., Erwin M.E., Anderson S.C. Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Diagn Microbiol Infect Dis. 21:1995;85-93.
28. Jorgensen J.H., Doern G.V., Maher L.A., Howell A.W., Redding J.S. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother. 34:1990;2075-2080.
29. Kitzis M.D., Acar J.F., Gutmann L. Antibacterial activity of meropenem against Gram-negative bacteria with a permeability defect and against staphylococci. J Antimicrob Chemother. 24:(suppl A):1989;125-132.
30. Klugman K., Goldstein F., Kohno S., Baquero F. The role of fourth-generation cephalosporins in the treatment of infections caused by penicillin-resistant streptococci. Clin Microbiol Infect. 3:(suppl 1):1997;S48-S60.
31. Knothe H., Shah P., Krcmery V., Antal M., Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefgamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection. 11:1983;315-317.
32. Kunin C.M. Editorial response antibiotic armageddon . Clin Infect Dis. 25:1997;240-241.
33. Labia R., Morand A., Tiwari K., Sirol D., Chanal C. Interactions of meropenem with β-lactamases including new enzymes with extended-spectrum activity against third-generation cephalosporins. J Antimicrob Chemother. 24:(suppl A):1989;219-223.
34. Leclercq R. Enterococci acquire new kinds of resistance. Clin Infect Dis. 24:(suppl 1):1997;S80-S84.
35. Livermore D.M., Yuan M. Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe. J Antimicrob Chemother. 38:1996;409-424.
36. Medeiros A.A. Evolution and dissemination of β-lactamases accelerated by generations of β-lactam antibiotics. Clin Infect Dis. 24:(suppl 1):1997;S19-S45.
37. Murray B.E. Diversity among multidrug-resistant enterococci. Emerg Infect Dis. 4:1998;37-47.
38. Eighth Informational Supplement for Approved Standard M7-A4 Methods for Dilution Antimicrobial Susceptibility Test for Bacteria That Grow Aerobically . 4th ed. 1998;National Committee for Clinical Laboratory Standards, Wayne, PA.
39. Noble W.C., Virani Z., Cree R.G.A. Co-transfer of vancomycin and other resistance genes from E. faecalis NCTC 12201 to S. aureus. FEMS Microbiol Lett. 93:1992;195-198.
40. Nord C.D., Lindmark A., Persson I. Susceptibility of anaerobic bacteria to meropenem. J. Antimicrob Chemother. 24:(suppl A):1989;113-117.
41. Panlilio A.L., Culver D.H., Gaynes R.P., Banerjee S., Henderson T.S., Tolson J.S., Markone W.J. Methicillin-resistant S. aureus in US hospitals, 1975-1991. Infect Control Hosp Epidemiol. 13:1992;582-586.
42. Pfaller M.A., Jones R.N. A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide. Diagn Microbiol Infect Dis. 28:1997;157-163.
43. Pitkin D.H., Sheikh W., Nadler H.L. Comparative in vitro activity of meropenem versus other extended-spectrum antimicrobials against randomly chosen and selected resistant clinical isolates tested in 26 North American Centers. Clin Infect Dis. 24:(suppl 2):1997;S238-S248.
44. Rassmussen BA, Bush K (1997) Carbapenem-hydrolyzing β-lactamases. Antimicrob Agents Chemother 41:233-232.
45. Rittenhouse S.F., Miller L.A., Kaplan R.L., Mosely G.H., Poupard J.A. A survey of β-lactamase-producing Haemophilus influenzae an evaluation of 5750 isolates . Diagn Microbiol Infect Dis. 21:1995;223-225.
46. Sader H.S., Pfaller M.A., Tenover F.C., Hollis R.J., Jones R.N. Evaluation and characterization of multi-resistant Enterococcus faecium from 12 US medical centers. J Clin Microbiol. 32:1994;2840-2842.
47. Sanders C.C., Sanders W.E., Thompson K.S., Iaconis J.P. Meropenem activity against resistant Gram-negative bacteria and interactions with β-lactamases . J Antimicrob Chemother. 24:(suppl A):1989;187-196.
48. Schaberg D.R., Culver D.H., Gaynes R.P. Major trends in the microbial etiology of nosocomial infection. Am J Med. 91:(suppl 3B):1991;72S-75S.
49. Schito G.C., Sanna A., Chezzi C., Ravizzola G., Leone F., Molinari G. In vitro activity of meropenem against clinical isolates in a multicentre study in Italy. J Antimicrob Chemother. 24:(suppl A):1989;57-72.
50. Senda K., Arakawa Y., Nakashima K., Ito H., Ichiyama S., Shimokata K., Kato N., Ohta M. Multifocual outbreaks of metallo-β-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum β-lactams, including carbapenems. Antimicrob Agents Chemother. 40:1996;349-353.
51. Swartz M.N. Hospital-acquired infections diseases with increasingly limited therapies . Proc Natl Acad Sci USA. 91:1994;2420-2427.
52. Thornsberry C., Ogilvie P., Kahn J., Mauriz Y. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. Diagn Microbiol Infect Dis. 29:1997;249-257.
53. Vercauteren E., Descheemaeker P., Ieven M., Sanders C.C., Goossens H. Comparison of screening methods for detection of extended-spectrum β-lactamases and their prevalence among blood isolates of Escherichia coli and Klebsiella spp. in a Belgian teaching hospital. J Clin Microbiol. 35:1997;2191-2197.
54. Wiedemann B., Zuhlsdorf M. Antibacterial properties of meropenem towards clinical isolates, β-lactamase producers and laboratory mutants. J Antimicrob Chemother. 24:(suppl A):1989;197-205.
55. Wiseman L.R., Wagstaff A.J., Brogden R.N., Bryson H.M. Meropenem a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy . Drugs. 50:1995;73-101.